Company news

Shield Therapeutics PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Results of 2022 General Meeting

July 27, 2022

Shield Therapeutics (STX): Looking to accelerat...

July 26, 2022

New Drug Submission accepted by Health Canada

July 14, 2022

Notice of General Meeting

July 8, 2022

2021 Annual Report and 2022 AGM Notice

June 30, 2022

KYE Pharmaceuticals Files Accrufer® NDS in Canada

March 21, 2022

Shield Therapeutics (STX) - PBMs have bought in...

March 2, 2022

Investor Presentation

February 25, 2022

KOL Investor Event on Iron Deficiency

February 4, 2022

Licence Agreement in Canada for Accrufer®

January 5, 2022

Patient Access Expands for Accrufer®

December 16, 2021

Shield Therapeutics (STX) Life Sciences Investo...

October 7, 2021

Jose A. Menoyo Appointed as Chief Medical Officer

September 27, 2021

Investor presentation

September 21, 2021

Shield Therapeutics (STX) - Focused on US marke...

August 20, 2021

Hardman & Co Video Event | Shield Therapeut...

August 12, 2021

AEGIS-CKD study results published in AJKD

August 9, 2021

US launch of Accrufer® confirmed for July 1, 2021

June 24, 2021

Directorate Change

June 18, 2021

Results of 2021 Annual General Meeting

June 17, 2021

Appointment of new Chief Executive Officer

May 28, 2021

Shield Therapeutics (STX): Accrufer launch on s...

May 26, 2021

US update

May 21, 2021

AEGIS-H2H study results published in IBD

May 18, 2021

Commencement of trading on the OTCQX Best Market

May 17, 2021

2020 Annual Report and 2021 AGM Notice

May 13, 2021

Appointment of Two Non-Executive Directors

May 10, 2021

Preliminary Results

April 29, 2021

Study demonstrates effectiveness of ferric maltol

March 26, 2021

Shield appoints new Chief Financial Officer

March 22, 2021

Australia's TGA approves Feraccru

March 9, 2021

PDMR/PCA Transaction Notification

March 4, 2021

Publication of Circular and Notice of GM

March 1, 2021

Successful completion of £25 million Fundraise

February 26, 2021

Shield Therapeutics (STX): Beefing up for the U...

February 2, 2021

Shareholder loan facilities

January 29, 2021

Director/PDMR Shareholding

January 21, 2021

Business and trading update

January 15, 2021

Shield Therapeutics (STX): Reassessing the US o...

January 6, 2021

PDMR Exercise of Share Options

December 18, 2020

Update re US partnering discussions

December 10, 2020

Withdrawal of all oppositions by TEVA

October 19, 2020

Shield Therapeutics (STX): Optimism over US deal

September 18, 2020

AEGIS-H2H study reanalysis

August 6, 2020

Total Voting Rights update

July 31, 2020

PT20 paper publication

July 16, 2020

Appointment of Non-Executive Director

June 26, 2020

Results of 2020 Annual General Meeting

June 18, 2020

Feraccru®/Accrufer® publications

June 3, 2020

Investor presentations

May 28, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 22 decks. Every deck is listed under its year.